Benny Green, MD
Family Medicine · Little Rock, ARNPI 1609873983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $629 and has fallen 84.1% since, to $100 in 2025.
Across 182 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$453
- Johnson & Johnson$319
- Novartis$298
- Acadia Pharmaceuticals Inc$199
- AbbVie$156
- Pfizer$139
- plus $1K from 35 others
Across 47 payments — averaging $3139.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$136K
- AstraZeneca$12K
What the payments were for
- Food & beverage$2,886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,886 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $152,323 |
| XareltoRivaroxaban | 264 | $97,884 |
| JardianceEmpagliflozin | 77 | $45,350 |
| JanuviaSitagliptin Phosphate | 82 | $43,461 |
| OzempicSemaglutide | 35 | $39,293 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $35,223 |
| MounjaroTirzepatide | 29 | $32,956 |
| RexultiBrexpiprazole | 46 | $31,457 |
| LinzessLinaclotide | 42 | $27,042 |
| Glatiramer Acetate | 11 | $24,916 |
| EntrestoSacubitril/Valsartan | 31 | $24,578 |
| GemtesaVibegron | 86 | $22,623 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $21,237 |
| FarxigaDapagliflozin Propanediol | 21 | $14,445 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $13,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $152,323385 claims |
| Johnson & JohnsonXarelto, Invokana | $319 | $104,875276 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $121 | $69,923126 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $41 | $59,309116 claims |
| Novo NordiskOzempic, Tresiba | $25 | $44,37949 claims |
| MerckJanuvia | $32 | $43,46182 claims |
| AbbVieLinzess, Namzaric | $156 | $33,23063 claims |
| Lilly USA, LLCMounjaro | $46 | $32,95629 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $76 | $31,45746 claims |
| NovartisEntresto | $298 | $24,57831 claims |
| AstraZenecaFarxiga | $90 | $14,44521 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $19 | $5,83422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- Harold BettonLittle Rock$18K
- Kevin RobertsLittle Rock$15K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
- Oksana MelnykLittle Rock$12K
- Thomas MooreLittle Rock$11K
- Patrick FieldsLittle Rock$10K
- Gilbert FosterLittle Rock$10K
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.